Ondine Biomedical (LON:OBI) was awarded the TAYYABA HASAN IMPACT AWARD at the 18th World Congress of International Photodynamic Association (IPA) in Finland for demonstrating “exceptional perseverance and clinical acumen.”
Ondine has demonstrated successful outcomes in a number of key studies for both prevention and treatment against strains of SARS-CoV-2, including deployment in large scale enterprises.
The IPA promotes the benefits of light-activated therapies to treat infections that pose the biggest threats to global health security.
The award to Ondine recognizes the collective efforts and successes in advancing the clinical safety and efficacy of photodynamic therapy for antiviral applications during the COVID-19 pandemic.
“The outcomes of this work and these studies will help to serve future pandemic preparedness and support the ongoing efforts for advanced antimicrobial resistance stewardship,” Colin Hopper, newly elected president of the IPA, said in a statement.
